Mavoglurant is primarily investigated for its potential in treating neurological and psychiatric conditions. It acts as a selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), which is implicated in various brain disorders. One of its key applications is in the treatment of Fragile X syndrome, a genetic condition that causes intellectual disability and behavioral challenges. By modulating glutamate signaling, it aims to improve cognitive function and reduce symptoms such as anxiety and hyperactivity. Additionally, mavoglurant has been explored for its role in addressing conditions like Parkinson's disease, where it may help manage levodopa-induced dyskinesia. Research is ongoing to evaluate its efficacy and safety in these therapeutic areas.